Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05241457 · ClinicalTrials.gov registry record

Achieving Meaningful Clinical Benchmarks With Ekso Gait Training During Acute Stroke Inpatient Rehabilitation.

A clinical trial of Stroke and Cerebrovascular Accident, sponsored by Sunnyview Rehabilitation Hospital.

Recruiting
Registry status
120
Enrollment target
1
Study location

NCT05241457: Recruiting study of Stroke and Cerebrovascular Accident, sponsored by Sunnyview Rehabilitation Hospital.

NCT05241457 is a study of Stroke and Cerebrovascular Accident that is actively recruiting participants, run by Sunnyview Rehabilitation Hospital. The registered enrollment target is 120 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05241457, a study of Stroke and Cerebrovascular Accident, is actively recruiting participants, sponsored by Sunnyview Rehabilitation Hospital.

RECRUITING
Registry status
120 participants
Enrollment target
1
Study location

Study Summary

The Ekso (Ekso Bionics) is a wearable exoskeleton that provides robotic support and walking assistance for patients with lower extremity paralysis. Research suggests that exoskeleton-assisted gait training is as effective as conventional gait training at improving walking outcomes and balance during both the chronic and subacute period following stroke (Goffredo et al., 2019; Molteni et al., 2017; Molteni et al., 2021; Nam et al., 2019; Rojek, 2019). Exoskeleton-assisted gait training during acute inpatient rehabilitation provides a means for patients to actively participate in gait training during the early and most severe stages of stroke recovery. Most acute inpatient rehabilitation facilities (IRFs) report a feasibility of 5-8 Ekso sessions during inpatient stays and demonstrate significant improvement from baseline (Nolan et al., 2020; Swank, 2020). Nolan et al. (2020) demonstrated that stroke patients receiving Ekso ambulated 1640 feet more than patients undergoing more conventional gait training techniques during inpatient rehabilitation, suggesting that the exoskeleton may offer additional benefit during this phase of recovery. Despite promising evidence, there have been no randomized controlled trials within the IRF setting. Because Ekso-gait training increases the number of steps patients can take, during acute inpatient physical therapy (PT), the investigators hypothesize that patients who participate in Ekso-gait training will demonstrate quicker improvements in balance, gait speed, endurance and independence in functional ambulation during their stay in the IRF. In this study, eligible patients admitted to Sunnyview Rehabilitation Hospital (SRH) for rehabilitation following stroke will be randomized to receive conventional or Ekso-gait training therapy. Meaningful clinical benchmarks for balance and walking will be assessed using the Berg Balance Scale (BBS) (Alghadir, 2018; Moore, 2018), the 10 Meter Walk Test (10MWT) (Bowden, 2008; Moore, 2018), th

Primary Outcome

Used to assess walking speed over a short distance at the patient's chosen speed.

Interventions

  • DEVICE Ekso gait training
  • PROCEDURE Standard physical therapy

Study Locations (1)

New York

  • Sunnyview - Schenectady

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2022-03-11
Est. Completion 2026-03

What NCT05241457 shows while recruiting

NCT05241457 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Ekso gait training is the first listed.

NCT05241457 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05241457 about?

NCT05241457 is a clinical study titled "Achieving Meaningful Clinical Benchmarks With Ekso Gait Training During Acute Stroke Inpatient Rehabilitation.". The Ekso (Ekso Bionics) is a wearable exoskeleton that provides robotic support and walking assistance for patients with lower extremity paralysis. Research suggests that exoskeleton-assisted gait training is as effective as conventional gait training at improving walking outcomes and balance during...

What is the current status of trial NCT05241457?

This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2022-03-11. Estimated completion is 2026-03.

What conditions does trial NCT05241457 study?

This clinical trial studies the following conditions: Stroke, Cerebrovascular Accident, Stroke, Acute, Cerebrovascular Accident, Acute.

What interventions are being tested in trial NCT05241457?

The interventions under investigation include: Ekso gait training (DEVICE), Standard physical therapy (PROCEDURE).

Who is sponsoring clinical trial NCT05241457?

This trial is sponsored by Sunnyview Rehabilitation Hospital, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05241457 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05241457's enrollment target sits among peer trials

120 117th of 454 higher than 329 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05241457, the US trial registry maintained by the National Library of Medicine. NCT05241457 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.